Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. - sprookjes - yvandenbroek - TriplyDB

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

http://www.wikidata.org/entity/Q34111120

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma Focus on adoptive T cell transfer trials in melanoma Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Updates in Therapy for Advanced Melanoma Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 Strategies for combining immunotherapy with radiation for anticancer therapy Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook Leveraging fluorinated glucosamine action to boost antitumor immunity Tumor infiltrating lymphocytes in ovarian cancer Advances in the treatment of metastatic melanoma: adoptive T-cell therapy T cell receptor-like recognition of tumor in vivo by synthetic antibody fragment Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.The use of immunotherapy in the treatment of melanoma Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.In vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomes Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.Regulation of cancer aggressive features in melanoma cells by microRNAs.Immunotherapy for metastatic solid cancers CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.Tissue biomarkers in melanoma patients treated with TIL Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.Therapeutic cancer vaccines: are we there yet?High-throughput identification of antigen-specific TCRs by TCR gene capture.

P2860

Q21131200-AD26CC47-C73D-42A0-8237-A506F20446B6 Q21245488-79C840B1-A7F5-419A-9390-CA8F52479E6C Q21328679-FA971A56-C4A8-4E7E-B68E-BC8D9A6A9C34 Q24596055-9D74284E-7857-46E8-8BE5-899AC3A6B5B5 Q24598792-1611D399-1EF0-47B3-B669-3926A8D82E29 Q26745444-FB51852E-E3ED-432F-B25F-65A3115820BD Q26771119-8CD7CDCA-8D20-4B16-A27D-3942F5057E63 Q26796316-BFD64A2B-4BDB-4558-AA2F-34714BFB184A Q26796675-07BA4036-616A-4665-9176-F0895819E0F4 Q26822793-13D939F6-3AAD-40F8-BDEC-01C32B415CE5 Q27002575-AC1116DC-7D73-4361-BF61-9EFCF4ABCA27 Q27004178-6F88DC3E-0866-4262-8C84-546EDF80DC0E Q27008230-EE2DA004-B263-4C26-8F9C-F5FF9DE3C69C Q27021878-81F3D3FE-8EAB-43F7-993C-6799FC06FFB9 Q27027803-5A35AFE8-9529-4AB4-B523-12A397EE1AFF Q27322455-6125CF99-4C32-4C2E-995F-CCAEEBDC7513 Q27345217-FBE35629-9C62-4DF0-8D04-CF255A2D3350 Q27686800-CF1EEFEA-556A-48BE-AA18-AE07C00D06B8 Q28068378-9F5C45C7-5B6D-4BE6-8D8D-B2CE8103078D Q28073563-B6089EAE-4709-498E-9EA6-44B519620B81 Q30573747-2813D1FE-D7E7-468D-9029-B115D4569D46 Q33593858-18241A70-C3D1-44F1-8D14-3E8171F7CE33 Q33688931-FF4272F7-0ED8-40D1-815C-AEBBC8F40D6B Q33716478-534286F4-6C74-4439-AB1E-B9A80619B358 Q33750205-DFB392CE-54AF-4461-8803-6A55546FDEAD Q33874986-4FEB5492-907E-4FD0-8B20-EF2F09784197 Q33889489-719FB71F-827A-4E9C-B0CA-656D5A100E36 Q34219970-6001F972-6DFE-4068-9140-76FD4BDFC2E5 Q34299986-61742ADD-4548-4AF8-BC2A-0574EF7B97AC Q34350259-617DD3DB-EC8E-4663-B034-99ABB994FAC5 Q34370215-EDD78515-198D-49FA-BC9E-D50F7CC21C2A Q34428963-1118D0E1-391B-4A1E-B71F-8FED3DCB0DF7 Q34458364-40723F65-B056-4D9E-BDB7-4FCE4612465E Q34531444-6E5F4307-4217-4EBC-AF9D-2FB18DC00E17 Q34603154-860ABB17-CD55-4571-BC67-B515C52484FC Q34618454-DF6694B6-0514-4233-B962-D5E455EBC4D6 Q34656292-AAF42998-38F0-4C03-A163-6A748FC5CC7B Q34757266-64065E1D-F69B-4C54-AE55-74304F132B38 Q34786691-06EDAC6C-D9F3-4344-BAE7-7B3A206FA334 Q35016476-3B43D39D-23CE-4EAD-AEFC-B23C52FE9C6E

P2860

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

http://www.wikidata.org/entity/Q34111120

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical responses in a phase ...... metastatic melanoma patients.

@ast

Clinical responses in a phase ...... metastatic melanoma patients.

@en

Clinical responses in a phase ...... metastatic melanoma patients.

@nl

type

label

Clinical responses in a phase ...... metastatic melanoma patients.

@ast

Clinical responses in a phase ...... metastatic melanoma patients.

@en

Clinical responses in a phase ...... metastatic melanoma patients.

@nl

prefLabel

Clinical responses in a phase ...... metastatic melanoma patients.

@ast

Clinical responses in a phase ...... metastatic melanoma patients.

@en

Clinical responses in a phase ...... metastatic melanoma patients.

@nl

P1433

Q34111120-99E9128C-5B29-41A9-89CD-66C974D423B5

P1476

Q34111120-C9316B4A-D4BE-4ECD-ABEA-676DE1C4FAF5

P2093

Q34111120-17BD7D2C-6647-4DE6-9B60-690C1F1FF852

Q34111120-19F733A6-181A-42DD-AC3B-A3894F1873FA

Q34111120-259BEED8-76DE-4F2C-8B9E-2ED621E136A3

Q34111120-579D30E1-24F7-4EEB-9D5A-6789FF747647

Q34111120-5DB0471C-591B-45AF-AD15-0A123978F6AF

Q34111120-6A99EC2C-2991-48AC-8AA3-855E20FA1F98

Q34111120-6FFDDBB8-5923-4421-8603-E6C28C4577E8

Q34111120-8985A2EC-C061-49BB-9773-569AE08B2302

Q34111120-8D85ACB9-DD7B-41B0-A53B-F339D90F7D9D

Q34111120-9D7439C5-C85C-470D-8FB2-2286CDC3DF23

P304

Q34111120-16A0DDAE-59E9-49C6-B6FE-9E09B6C02B25

P31

Q34111120-92A1A237-E999-4459-8CEB-C13928543C87

P356

Q34111120-22E8A038-FF40-4EEC-9AC2-54724E4B4C05

P407

Q34111120-5D22C946-EBBA-4A98-83B1-AD68E283B4BA

P433

Q34111120-2BAE4B19-4CE5-4087-9D69-42B1E0D64A68

P478

Q34111120-F4B0C7CC-A6C8-4720-A2E0-3D3F8B5352B5

P577

Q34111120-DD6A215A-C6EA-49B3-90DF-842A772FAF84

P698

Q34111120-013BE574-DD01-4AE2-96E6-FF4E80E05C9F

P356

1078-0432.CCR-10-0041

P1433

Clinical Cancer Research

P1476

Clinical responses in a phase ...... metastatic melanoma patients.

@en

P2093

Adva Kubi

http://www.w3.org/2001/XMLSchema#string

Alon Ben-Nun

http://www.w3.org/2001/XMLSchema#string

Arnon Nagler

http://www.w3.org/2001/XMLSchema#string

Avichai Shimoni

http://www.w3.org/2001/XMLSchema#string

Avraham J Treves

http://www.w3.org/2001/XMLSchema#string

Bruria Shalmon

http://www.w3.org/2001/XMLSchema#string

Daphna Levy

http://www.w3.org/2001/XMLSchema#string

Dov Zippel

http://www.w3.org/2001/XMLSchema#string

Einat Hovav

http://www.w3.org/2001/XMLSchema#string

Gal Markel

http://www.w3.org/2001/XMLSchema#string

P304

2646-2655

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0041

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20406835

http://www.w3.org/2001/XMLSchema#string